Lipocine (LPCN) Cash from Investing Activities (2012 - 2025)

Lipocine (LPCN) has 14 years of Cash from Investing Activities data on file, last reported at $701449.0 in Q3 2025.

• Quarterly Cash from Investing Activities fell 31.4% year-over-year to $701449.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $5.1 million (up 15.16% YoY) and the FY2024 annual result came in at $2.4 million, down 81.31% from the prior year.
• Cash from Investing Activities declined to $701449.0 in Q3 2025, from $4.5 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $7.3 million in Q1 2022 to a low of -$34.0 million in Q1 2021.
• A 5-year average of -$507187.7 and a median of $1.2 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2021 — Cash from Investing Activities slumped 971.15% — and 2022, when it soared 364.53%.
• Tracing LPCN's Cash from Investing Activities over 5 years: stood at -$9.7 million in 2021, then surged by 126.7% to $2.6 million in 2022, then climbed by 5.02% to $2.7 million in 2023, then tumbled by 72.09% to $761058.0 in 2024, then fell by 7.83% to $701449.0 in 2025.
• The last three Cash from Investing Activities figures came in at $701449.0 (Q3 2025), $4.5 million (Q2 2025), and -$882073.0 (Q1 2025), per Business Quant data.